DIPG-77. INTRATUMORAL PHARMACOKINETICS OF CHEMOTHERAPY IN DIPG: XENOGRAFT AND INITIAL PHASE 0 CLINICAL TRIAL RESULTS

摘要

INTRODUCTIONHundreds of chemotherapy trials have been conducted in diffuse intrinsic pontine glioma (DIPG) without survival improvement. One potential reason is a lack of intratumoral penetration, but this has not previously been assessed in humans. We used gemcitabine as a model agent to assess DIPG intratumoral pharmacokinetics (PK). We chose gemcitabine for its known blood-brain barrier penetration and established pediatric safety data.